Brief news reports on Tuberculosis

6th Global Forum on TB Vaccines shifts to virtual format

In response to the increase in rates of COVID-19 infection and the rapid spread of the Omicron variant, and recognizing the challenges and uncertainties around changing travel restrictions and local and regional mandates, the 6th Global Forum on TB Vaccines will be convened as a fully virtual event. To facilitate participation, it will now take place over four days, from 22-25 February 2022. Read the full COVID-19 statement here.

Read More →

RESIST-TB webinar: Pediatric PK for the new and repurposed TB drugs – Where are we now?

RESIST-TB will host a webinar on the latest developments in pediatric pharmacokinetics (PK) of bedaquiline, linezolid, delamanid and pretomanid on 26 January 2022.

Read More →

Computational models move researchers closer to TB vaccine

According to a 2021 World Health Organization report, the global COVID-19 pandemic caused an increase in tuberculosis (TB) deaths – 1.5 million in 2020 versus 1.4 million in 2019 – due to a lack of efficient diagnosis and treatment. Since TB has been the number one cause of death from infectious disease in the world for centuries, University of Michigan (UM) Medical School Professor Denise Kirschner and colleagues have been working to better understand the disease by using supercomputers like Expanse at the San Diego Supercomputer Center at UC San Diego.

Read More →

TB vaccine could assist future COVID-19 vaccine development

Despite unprecedented efforts to develop COVID-19 vaccines in record time amid the global pandemic, SARS-CoV-2 continues to spread rapidly with the emergence of new variants, such as delta and omicron, making the development of new therapeutic strategies critically important.  

Read More →

Culture-based screening in US-bound individuals reduced multidrug-resistant TB incidence

Overseas culture-based tuberculosis screening in U.S.-bound immigrants and refugees substantially reduced the importation of multidrug-resistant TB into the U.S., researchers reported.

Read More →

Why has the incidence of TB not reduced in London during the COVID-19 pandemic?

The rate of TB in London, UK, has not reduced during the COVID-19 pandemic. This might be surprising given that TB is airborne, and suggests important lessons about the transmission and treatment of the disease.

Read More →

‘Fighting TB in South Asia challenge in pandemic times’

Although the incidents of tuberculosis have decreased in South Asia from 5.4 million cases in 2000 to 3.8 million in 2020, the health experts believe that the still staggering numbers call for effective policies.

Read More →

Measuring impact of drugs on global health can aid in identifying shortcomings

BINGHAMTON, N.Y., 11-Jan-2022 – A common framework that standardizes health impact across diseases and their interventions can aid in identifying current shortcomings on a global scale, according to new research from Binghamton University, State University of New York.

Read More →

Underfunded and deadly TB needs its own Bill Gates

Global efforts to end tuberculosis (TB) are futile without dedicated investment in research into the debilitating disease that is killing 4000 people a day, Stop TB Partnership warns.

Read More →

Drug-resistant TB in Afghanistan: We must continue to put people at the centre of treatment

In recent years, Médecins Sans Frontières (MSF) has been able to improve patients' experiences of care for drug-resistant TB in Afghanistan, but the changing political situation in the country threatens to derail this progress. Anita Mesic, MSF TB, HIV, and hepatitis adviser reports in The BMJ.

Read More →

Page 1 of 781 · Total posts: 10

1 2 Last→